Synopsis X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. The present study aims to evaluate the efficacy and safety of burosumab in children with X-linked hypophosphatemia. This week’s “ MED FACT ” discusses a clinical trial from The New England Journal Of Medicine, “ Burosumab Therapy in Children With X-Linked Hypophosphatemia”. Authors: Thomas O.
Carpenter et. al. Key Takeaways Treatment with burosumab improves renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets in children with X-linked hypophosphatemia. Objective: To evaluate the efficacy and safety of burosumab in children with X-linked hypophosphatemia Study type: Phase 2 trial…
